← Back to Search

Targeted Antibiotic Therapy for Pneumonia

N/A
Recruiting
Led By Michael Rothberg, M.D.
Research Sponsored by The Cleveland Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Men or women greater than or equal to 18 years of age
Admitting diagnosis of pneumonia
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from 48 hours to 21 days
Awards & highlights

Study Summary

This trial will test if reducing exposure to broad-spectrum antibiotics can help detect & reduce infections faster.

Who is the study for?
This trial is for adults over 18 with pneumonia, admitted to a participating hospital without intensive care in the first 24 hours, not on comfort care only, without cystic fibrosis or recent discharge from acute care. It excludes those known to have a specific pathogen causing their illness.Check my eligibility
What is being tested?
The study tests if rapid diagnostic testing and pharmacist-led de-escalation can reduce broad-spectrum antimicrobial use in community-acquired pneumonia. It's a 3-year trial with four groups: one gets rapid tests, another gets pharmacist help, one gets both, and the last follows usual care.See study design
What are the potential side effects?
While this trial focuses on treatment processes rather than drugs themselves, potential side effects may include discomfort from diagnostic procedures or changes in medication management by pharmacists.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have been diagnosed with pneumonia.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 months after discharge
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months after discharge for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of days of broad-spectrum antibiotic therapy
Secondary outcome measures
14-day mortality
30-day mortality
30-day readmission (yes/no)
+18 more

Trial Design

4Treatment groups
Active Control
Group I: Rapid diagnostic testing (RDT)Active Control1 Intervention
Rapid diagnostic testing: Eligible patients at hospitals randomized to this arm will undergo testing for viral pathogens (from November-April) and pneumococcal UAT testing. If the patient is not being admitted to the ICU, and the patient has an admitting diagnosis of pneumonia, the form will append orders for viral testing and UAT testing to providers in hospitals randomized to receive it.
Group II: Pharmacist-led de-escalationActive Control1 Intervention
Pharmacist-led de-escalation: Another CDSS algorithm will identify CAP patients who meet study criteria and have negative culture results for > 48 hours and generate a list for the clinical pharmacist, who will be a member of the study team. The alerts will be audited by the pharmacist daily on weekdays at a centralized location. The pharmacist will attempt to determine whether each patient is clinically stable. The validated measures of clinical stability in patients with CAP are a) resolved vital sign abnormalities b) normal mental status c) ability to eat. If the patient appears stable, the pharmacist will communicate their recommendations for de-escalation to the clinical providers via a phone call or page.
Group III: Rapid diagnostic testing (RDT) and Pharmacist-led de-escalationActive Control2 Interventions
Rapid diagnostic testing: Eligible patients at hospitals randomized to this arm will undergo testing for viral pathogens (from November-April) and pneumococcal UAT testing. If the patient is not being admitted to the ICU, and the patient has an admitting diagnosis of pneumonia, the form will append orders for viral testing and UAT testing to providers in hospitals randomized to receive it. Pharmacist-led de-escalation: Another CDSS algorithm will identify CAP patients who meet study criteria and have negative culture results for >48-hours and generate a list for the clinical pharmacist, who will be a member of the study team. The alerts will be audited by the pharmacist daily on weekdays at a centralized location. The pharmacist will attempt to determine whether each patient is clinically stable. If the patient appears stable, the pharmacist will communicate their recommendations for de-escalation to the clinical providers via a phone call or page.
Group IV: Usual care (no intervention)Active Control1 Intervention
Usual care

Find a Location

Who is running the clinical trial?

The Cleveland ClinicLead Sponsor
1,022 Previous Clinical Trials
1,353,250 Total Patients Enrolled
Michael Rothberg, M.D.Principal InvestigatorThe Cleveland Clinic
1 Previous Clinical Trials
3,000 Total Patients Enrolled

Media Library

Rapid diagnostic testing (RDT) Clinical Trial Eligibility Overview. Trial Name: NCT05568654 — N/A
Community-acquired Pneumonia Research Study Groups: Rapid diagnostic testing (RDT), Pharmacist-led de-escalation, Rapid diagnostic testing (RDT) and Pharmacist-led de-escalation, Usual care (no intervention)
Community-acquired Pneumonia Clinical Trial 2023: Rapid diagnostic testing (RDT) Highlights & Side Effects. Trial Name: NCT05568654 — N/A
Rapid diagnostic testing (RDT) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05568654 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants have contributed to this research endeavor?

"Affirmative. The clinicaltrials.gov website reveals that the trial, which first went live on November 1st 2022, is still in search of participants. A total of 12500 patients must be recruited from 4 distinct sites to complete the study."

Answered by AI

Are there any Canadian medical facilities conducting this research project?

"As of right now, the 4 sites running this medical trial are located in Avon, Fairview Park, Garfield Heights and multiple other areas. To facilitate participation, it is advisable to pick the closest clinic available so that any travel demands can be minimized."

Answered by AI

Does this research offer any vacancies for participants?

"Affirmative. As per the information available on clinicaltrials.gov, this medical trial remains open and is currently seeking participants. It was announced on November 1st 2022 with a subsequent update made 13 days later; 12500 individuals are required to be recruited from 4 different medical centres."

Answered by AI

Who else is applying?

What state do they live in?
Ohio
What site did they apply to?
Lutheran Hospital
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
0
~7237 spots leftby Jan 2026